Evidence map›Paper›PMID 35292529›Full record

ArticleRMD open2022

Frailty in rheumatoidrmdopen-2021-002111 arthritis and its relationship with disease activity, hospitalisation and mortality: a longitudinal analysis of the Scottish Early Rheumatoid Arthritis cohort and UK Biobank.

Peter Hanlon, Fraser Morton, Stefan Siebert, Bhautesh D Jani, Barbara I Nicholl, Jim Lewsey, David McAllister, Frances S Mair

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Peter HanlonGeneral Practice and Primary Care, University of Glasgow Institute of Health and Wellbeing, Glasgow, UK peter.hanlon@glasgow.ac.uk.ORCID 0000-0002-5828-3934
Fraser MortonInstitute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK.
Stefan SiebertInstitute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK.
Bhautesh D JaniGeneral Practice and Primary Care, University of Glasgow Institute of Health and Wellbeing, Glasgow, UK.
Barbara I NichollGeneral Practice and Primary Care, University of Glasgow Institute of Health and Wellbeing, Glasgow, UK.
Jim LewseyHealth Economics and Health Technology Assessment, University of Glasgow Institute of Health and Wellbeing, Glasgow, UK.
David McAllisterPublic Health, University of Glasgow Institute of Health and Wellbeing, Glasgow, UK.
Frances S MairGeneral Practice and Primary Care, University of Glasgow Institute of Health and Wellbeing, Glasgow, UK.
University of Glasgow · GB

Funding

Medical Research Council MC_PC_17228Medical Research Council MC_QA137853Medical Research Council MR/S021949/1Versus Arthritis 21970
6 · The paper itself

Abstract

objectiveTo assess the prevalence of frailty in rheumatoid arthritis (RA) and its association with baseline and longitudinal disease activity, all-cause mortality and hospitalisation.

participantsPeople with RA identified from the Scottish Early Rheumatoid Arthritis (SERA) inception cohort (newly diagnosed, mean age 58.2 years) and UK Biobank (established disease identified using diagnostic codes, mean age 59 years). Frailty was quantified using the frailty index (both datasets) and frailty phenotype (UK Biobank only). Disease activity was assessed using Disease Activity Score in 28 joints (DAS28) in SERA. Associations between baseline frailty and all-cause mortality and hospitalisation was estimated after adjusting for age, sex, socioeconomic status, smoking and alcohol, plus DAS28 in SERA.

resultsBased on the frailty index, frailty was common in SERA (12% moderate, 0.2% severe) and UK Biobank (20% moderate, 3% severe). In UK Biobank, 23% were frail using frailty phenotype. Frailty index was associated with DAS28 in SERA, as well as age and female sex in both cohorts. In SERA, as DAS28 lessened over time with treatment, mean frailty index also decreased. The frailty index was associated with all-cause mortality (HR moderate/severe frailty vs robust 4.14 (95% CI 1.49 to 11.51) SERA, 1.68 (95% CI 1.26 to 2.13) UK Biobank) and unscheduled hospitalisation (incidence rate ratio 2.27 (95% CI 1.45 to 3.57) SERA 2.74 (95% CI 2.29 to 3.29) UK Biobank). In UK Biobank, frailty phenotype also associated with mortality and hospitalisation.

conclusionFrailty is common in early and established RA and associated with hospitalisation and mortality. Frailty in RA is dynamic and, for some, may be ameliorated through controlling disease activity in early disease.

Indexed as

Arthritis, RheumatoidFrailtyBiological Specimen BanksFemaleHospitalizationHumansScotlandUnited Kingdomepidemiologypatient reported outcome measuresrheumatoid arthritis

Identifiers

PMID35292529
PMCPMC8928366
OpenAlexW4221031766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.